The FDA delegation also included Sarah McMullen, the Country Director at the FDA China Office, and Jessica Stewart, Senior Public Health Advisor. Ten representatives from member companies across the pharmaceutical, medical devices, and healthcare services sectors participated in the discussion.
During the discussion, Hart outlined the Chamber’s efforts to facilitate US-China regulatory communication and policy exchange in the healthcare sector. He noted that US healthcare companies in China continue to increase investment in R&D, innovation, and quality management, contributing to the development of China’s healthcare system and better patient outcomes. Companies remain broadly focused on the stability, transparency, and predictability of regulatory policies, and hope to maintain smooth communication with both US and Chinese regulators on issues such as product registration and review, quality supervision, and cross-border collaboration. The Chamber will continue to convey these priorities and support practical, ongoing dialogue between industry and government.
The US representatives discussed the FDA’s key priorities and initiatives in pharmaceutical regulation and responded to common issues raised by US companies operating in China. Abdoo noted that the FDA places strong importance on engagement with Chinese regulatory authorities and industry organizations, and expressed a willingness to maintain regular, professional exchanges on areas such as pharmaceutical regulation and quality system development in both countries.
The meeting provided an opportunity for attendees to exchange views on industry trends, the regulatory environment, the application of artificial intelligence, and international cooperation. The FDA expressed its commitment to maintaining regular communication with AmCham China and looks forward to following up on specific issues through the Chamber to jointly support the high-quality development of the US-China pharmaceutical and medical industries.
